Please login to the form below

Not currently logged in
Email:
Password:

GLP1 agonists

This page shows the latest GLP1 agonists news and features for those working in and with pharma, biotech and healthcare.

EMA: no new safety concerns with GLP-1 diabetes drugs

EMA: no new safety concerns with GLP-1 diabetes drugs

The GLP-1 based therapy class includes both glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors.

Latest news

  • US charity calls for release of diabetes drug data US charity calls for release of diabetes drug data

    The concerned products comprise GLP-1 agonists, such as Byetta/Bydureon (exenatide) from Amylin/ Bristol Myers Squibb (BMS) and Victoza (liraglutide) from Novo Nordisk, as well as the DPP-4 inhibitors, ... data that reinforced "growing safety concerns"

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... agonists (T2D and obesity). Development, Commercialisation

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

brian smith science of the deal
The science of the deal
Business development is more like child-raising than you might think...
The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...

Infographics